Project Grant R01TW013366
Award Date 8/20/26
Completion Date 5/31/31
Dollars Obligated $578K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of California, San Francisco $2,493,062 on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine implementation, effectiveness, and cost-effectiveness of two strategies for integrating community health worker-facilitated hypertension telehealth into routine primary health centers operated by Kenya's Ministry of Health. The study compares a core implementation...
- The Department of Health and Human Services National Institutes of Health Fogarty International Center awarded the University of Washington $417,681 on August 20, 2026, under the International Research and Research Training program (CFDA 93.989) to develop and evaluate a Systems Analysis and Improvement Approach to optimize cardiometabolic care delivery for hypertension and type 2 diabetes in central Mozambique. The recipient will apply the SAIA implementation strategy to improve diagnosis and...
- The National Institutes of Health Fogarty International Center awarded the University of Southern California $750,638 on September 15, 2025, under the International Research and Research Training program (CFDA 93.989) to build local capacity for timely diagnosis of multiple sclerosis and prevention of disability in Colombia. The award funds three specific aims: identifying barriers that healthcare providers experience in diagnosing MS, examining illness perceptions and attitudes among patients...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $2,656,944 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, to establish and conduct the Uganda Lung Health Study, a five-year observational cohort investigating the intersection of HIV, sex, and chronic obstructive pulmonary disease risk across the adult lifespan in sub-Saharan Africa. The study will enroll 800 adolescents and adults aged 16–90 years, balanced by sex and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $868,048 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study of airway dysanapsis and early-life risk factors for chronic obstructive pulmonary disease. The research, titled Predictors of Airway Dysanapsis in Early Life (PADEL), leverages eight longitudinal birth cohorts to examine relationships between early-life exposures...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $2,141,996 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and implement Community Vital Signs (CVS) strategies for identifying undiagnosed hypertension in Nigeria. The project adapts community-based screening interventions to increase blood pressure screening among adults over 18 years of age and connect patients to primary care for hypertension...
- The National Heart Lung and Blood Institute awarded New York University School of Medicine $186,706 for a K23 Career Development Award on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will evaluate multi-level contexts and barriers affecting primary care clinicians' prescribing of remote patient monitoring (RPM) for hypertension management, then design and test an electronic health record-based prescribing workflow (EHR-RPM) to increase RPM...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $942,143 on September 25, 2025, to evaluate implementation of the World Health Organization's HEARTS hypertension and diabetes primary care model in Guatemala's Ministry of Health system under Assistance Listing 93.837 (Cardiovascular Diseases Research). The University of Michigan study team will conduct a mixed-methods evaluation spanning a 30-month implementation period followed by a 30-month...